Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline up to week 52
Awards & highlights
Study Summary
This trial tests the safety and effectiveness of a new injectable drug for knee pain caused by osteoarthritis.
Who is the study for?
Adults over 18 with knee osteoarthritis who haven't found pain relief from standard treatments can join. They must meet specific criteria for the severity of their condition and not have other knee issues or sensitivities to components like capsaicin. Recent surgery, significant trauma, or participation in another drug trial disqualifies them.Check my eligibility
What is being tested?
The trial is testing RTX-GRT7039 against a placebo in patients with knee osteoarthritis pain. Participants will receive repeated injections to see if it's effective and safe compared to no active treatment. The study randomly assigns participants to either the test drug or placebo group without them knowing which one they're getting.See study design
What are the potential side effects?
While the potential side effects are not listed here, similar compounds like capsaicin may cause local reactions such as burning or stinging at the injection site, increased knee pain, swelling, and possible allergic reactions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline up to week 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline up to week 52
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Secondary outcome measures
Change From Baseline in 36-Item Short-Form (SF-36) Domain Scores
Change From Baseline in EuroQol-5 Dimension Health Questionnaire 5 Levels (EQ-5D-5L) Score
Change from Baseline in WOMAC A1 (Walking Pain) Subscale Score
+9 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: RTX-GRT7039Experimental Treatment1 Intervention
Participants will receive 2 intra-articular injections of RTX-GRT7039 during the 52-week double-blind treatment period.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive 2 intra-articular injections of placebo matching to RTX-GRT7039 during the 52-week double-blind treatment period.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for osteoarthritis (OA) include nonsteroidal anti-inflammatory drugs (NSAIDs), duloxetine, and intraarticular injections. NSAIDs work by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), reducing inflammation and pain.
Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), modulates pain by increasing neurotransmitter levels in the brain and spinal cord. Intraarticular injections, such as corticosteroids, provide localized anti-inflammatory effects.
Investigational treatments like platelet-rich plasma (PRP) aim to reduce inflammation and promote tissue repair through growth factors, while gene therapies like TissueGene-C target cellular pathways to improve cartilage health. Understanding these mechanisms helps OA patients and their doctors choose the most appropriate treatment based on the specific pathways involved in their symptoms.
Pathophysiology and first-line treatment of osteoarthritis.A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip.
Pathophysiology and first-line treatment of osteoarthritis.A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip.
Find a Location
Who is running the clinical trial?
Grünenthal GmbHLead Sponsor
97 Previous Clinical Trials
33,618 Total Patients Enrolled
12 Trials studying Osteoarthritis
8,808 Patients Enrolled for Osteoarthritis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have other health conditions that could make it difficult to evaluate the condition of your knee during the trial.You have pain near a joint that is not caused by osteoarthritis, such as pain from another condition or injury.You have certain conditions in your knee joint that make you ineligible for the study, such as osteonecrosis, severe arthritis, or knee pain caused by something other than arthritis.You have had allergic reactions to resiniferatoxin (RTX) or similar substances like capsaicin found in chili peppers.You have tried the standard treatment for your pain before, but it didn't work well enough for you.
Research Study Groups:
This trial has the following groups:- Group 1: RTX-GRT7039
- Group 2: Placebo
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger